Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -194.74% is 99% above its 5-year average of -17394.61%, near the high end of its 5-year range (-4967100.00%–169910.53%).
99.77% above its 12-month average of -86349.02%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1929.01%.
NET PROFIT MARGIN
-194.74%
NET PROFIT MARGIN AVG TTM
-86349.02%
NET PROFIT MARGIN AVG 3Y
-130155.63%
NET PROFIT MARGIN AVG 5Y
-17394.61%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+99.77%
CURRENT VS 3Y AVG
+99.85%
CURRENT VS 5Y AVG
+98.88%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 724 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
4D Molecular Therapeutics, Inc.
Market Cap
$670.70M
Net Profit Margin
-194.74%
TTM Avg
-86349.02%
3Y Avg
-130155.63%
5Y Avg
-17394.61%
Market Cap
$669.77M
Net Profit Margin
1.76%
TTM Avg
11.88%
3Y Avg
8.37%
5Y Avg
1.42%
Market Cap
$680.31M
Net Profit Margin
329.09%
TTM Avg
-11813.45%
3Y Avg
-10636.53%
5Y Avg
-14431.57%
Market Cap
$689.73M
Net Profit Margin
-4619.67%
TTM Avg
-3871.87%
3Y Avg
-2595.36%
5Y Avg
-1815.29%
Market Cap
$642.27M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$637.17M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$648.75M
Net Profit Margin
-115.18%
TTM Avg
-291.05%
3Y Avg
-192.01%
5Y Avg
-153.55%
Market Cap
$714.33M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 4D Molecular Therapeutics, Inc. (FDMT) | $670.70M | -194.74% | -86349.02% | -130155.63% | -17394.61% |
| Annexon, Inc. (ANNX)vs › | $681.58M | 0.00% | 0.00% | 0.00% | 0.00% |
| MiMedx Group, Inc. (MDXG)vs › | $669.77M | 1.76% | 11.88% | 8.37% | 1.42% |
| Helus Pharma Inc. (HELP)vs › | $680.31M | 329.09% | -11813.45% | -10636.53% | -14431.57% |
| Anteris Technologies Global Corp. (AVR)vs › | $689.73M | -4619.67% | -3871.87% | -2595.36% | -1815.29% |
| ArriVent BioPharma, Inc. (AVBP)vs › | $642.27M | 0.00% | 0.00% | 0.00% | 0.00% |
| Aura Biosciences, Inc. (AURA)vs › | $637.17M | 0.00% | 0.00% | 0.00% | 0.00% |
| OmniAb, Inc. (OABI)vs › | $648.75M | -115.18% | -291.05% | -192.01% | -153.55% |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $714.33M | 0.00% | 0.00% | 0.00% | 0.00% |
| Climb Bio, Inc. (CLYM)vs › | $633.33M | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
-187.2%
Net Profit Margin
-194.7%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -1929.01% |
| 2026-03-31 | -2256.65% |
| 2025-12-31 | 22.80% |
| 2025-09-30 | -63195.56% |
| 2025-06-30 | -364386.67% |
| 2025-03-31 | -342657.14% |
| 2024-12-31 | -4967100.00% |
| 2024-09-30 | -1461433.33% |
| 2024-06-30 | -699060.00% |
| 2024-03-31 | -115717.86% |
| 2023-12-31 | 169910.53% |
| 2023-09-30 | -50.76% |
| 2023-06-30 | -12391.63% |
| 2023-03-31 | -9624.83% |
| 2022-12-31 | -2195.59% |
| 2022-09-30 | -5138.20% |
| 2022-06-30 | -17337.04% |
| 2022-03-31 | -2160.62% |
| 2021-12-31 | -27264.13% |
| 2021-09-30 | -1628.04% |
| 2021-06-30 | -52.05% |
| 2021-03-31 | -820.30% |
| 2020-12-31 | 2103.07% |
| 2020-09-30 | -105.55% |
| 2020-06-30 | -417.09% |
| 2020-03-31 | -372.28% |
| 2019-12-31 | -793.84% |
| 2019-09-30 | -3087.96% |
| 2019-06-30 | -374.00% |
| 2019-03-31 | -374.00% |
| 2018-12-31 | -48.17% |
| 2018-09-30 | -48.17% |
| 2018-06-30 | -102.31% |
| 2018-03-31 | -102.31% |
